CenTrak Named Global Healthcare RTLS Company of the Year by Frost & Sullivan
October 10, 2024 09:05 ET
|
CenTrak, Inc.
CenTrak recognized as a global RTLS leader for its scalable location data and comprehensive suite of solutions on a unified platform
Amwell expands clinical programs portfolio to include Hello Heart cardiovascular health risk management solution
October 08, 2024 07:05 ET
|
Amwell
Amwell today announced Hello Heart is a partner in the Amwell clinical programs portfolio available on the Amwell Converge™ platform.
Temperature Monitoring Devices Market to be Worth USD 5.3 billion by 2034, growing a CAGR 4.5% - Transparency Market Research, Inc.
October 01, 2024 08:55 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The global temperature monitoring devices market (온도 모니터링 장치 시장) is estimated to surge at...
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
September 30, 2024 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE...
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
September 11, 2024 08:55 ET
|
PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
Key Highlights of Lighthouse Fusion
August 27, 2024 09:00 ET
|
Lighthouse Autism Center
Lighthouse Autism Center expands its speech therapy program with more dually certified SLPs and BCBAs, offering better outcomes for children with autism.
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024 18:18 ET
|
PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
August 07, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
August 06, 2024 08:00 ET
|
Compass Therapeutics
Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic...
SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography
July 16, 2024 12:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will be presenting new findings on...